SNDX
Syndax·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNDX
Syndax Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing therapies for the treatment of resistant cancers
730 Third Avenue, 9th Floor, New York, New York 10017
--
Syndax Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on October 11, 2005. The company is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company is developing revumenib, a potent, selective, small molecule inhibitor of menin-MLL binding interactions, for the treatment of KMT2A rearrangement or KMT2AR, also known as mixed-lineage leukemia rearrangement or MLLR, acute leukemia including acute lymphoblastic leukemia or ALL, and acute myeloid leukemia or AML, and necleophosmin 1, Also known as NPM 1, mutant AML.
Earnings Call
Q2/2025
Estimate EPS-1
Actual EPS-0.83
Estimate Revenue26.64M
Actual Revenue37.96M
Syndax Pharmaceuticals' Q2 2025: Unpacking Key Contradictions in Revuforj's Impact on Patient Care and Market Growth
Aug 04,2025 11:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SNDX has released its 2025 Q3 earnings. EPS was reported at -0.7, versus the expected -0.71, beating expectations. The chart below visualizes how SNDX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SNDX has released its 2025 Q3 earnings report, with revenue of 45.87M, reflecting a YoY change of 266.97%, and net profit of -60.72M, showing a YoY change of 27.83%. The Sankey diagram below clearly presents SNDX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
